{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T10:32:57Z","timestamp":1758709977899,"version":"3.43.0"},"reference-count":6,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.ejca.2019.01.012","type":"journal-article","created":{"date-parts":[[2019,2,5]],"date-time":"2019-02-05T13:48:42Z","timestamp":1549374522000},"page":"8-10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Prurigo nodularis and pembrolizumab: A therapeutic challenge"],"prefix":"10.1016","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1925-1243","authenticated-orcid":false,"given":"Davide","family":"Fattore","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7610-9270","authenticated-orcid":false,"given":"Luigia","family":"Panariello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Carmela","family":"Annunziata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"Fabbrocini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejca.2019.01.012_bib1","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy","volume":"19","author":"Sibaud","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.ejca.2019.01.012_bib2","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ejca.2018.08.022","article-title":"Bullous pemphigoid and nivolumab: dermatologic management to support and continue oncologic therapy","volume":"103","author":"Panariello","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2019.01.012_bib3","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2019.01.012_bib4","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/ejp.767","article-title":"The pathogenesis of Prurigo nodularis \u2013 \u2018Super-Itch\u2019 in exploration","volume":"20","author":"Zeidler","year":"2016","journal-title":"Eur J Pain"},{"key":"10.1016\/j.ejca.2019.01.012_bib5","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1159\/000446049","article-title":"Prurigo nodularis management","volume":"50","author":"Tsianakas","year":"2016","journal-title":"Curr Probl Dermatol"},{"issue":"10","key":"10.1016\/j.ejca.2019.01.012_bib6","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.amjmed.2005.05.031","article-title":"Efficacy of lidocaine in the treatment of pruritus in patients with chronic cholestatic liver diseases","volume":"118","author":"Villamil","year":"2005","journal-title":"Am J Med"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804919300243?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804919300243?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T20:19:54Z","timestamp":1754684394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804919300243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":6,"alternative-id":["S0959804919300243"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2019.01.012","relation":{},"ISSN":["0959-8049"],"issn-type":[{"type":"print","value":"0959-8049"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prurigo nodularis and pembrolizumab: A therapeutic challenge","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2019.01.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}